{"id":"W2336162936","doi":"10.1200/jco.2013.31.15_suppl.9013","title":"An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Internal medicine; Dacarbazine; Hazard ratio; Progression-free survival; Oncology; Vemurafenib; Melanoma; Clinical endpoint; Adverse effect; Phases of clinical research; Gastroenterology; Chemotherapy; Randomized controlled trial; Confidence interval; Cancer; Cancer research; Metastatic melanoma; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00265814,0.0002559802,0.001685278,0.0001525275,0.00004431988,0.00003056013,0.0002881155,0.0003362279,0.0001182283],"category_scores_gemma":[0.002107762,0.0001709148,0.0003666063,0.000121927,0.0002281922,0.00004263883,0.00004368966,0.0004928982,0.00002300716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005127873,"about_ca_system_score_gemma":0.0005879678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004434656,"about_ca_topic_score_gemma":0.00007887163,"domain_scores_codex":[0.9949425,0.001791055,0.002246648,0.0003672261,0.0003435808,0.0003089696],"domain_scores_gemma":[0.9957676,0.001158037,0.001917246,0.0003079226,0.0004999573,0.0003492527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.956968,0.005138884,0.0004488684,0.000006308425,0.0006276268,0.0001484102,0.0000703799,0.00007125195,0.001071039,0.0001176796,0.000704245,0.0346273],"study_design_scores_gemma":[0.9184589,0.07360778,0.004104126,0.00003118644,0.0003642235,0.00002529909,0.00005674515,0.0002354481,0.001368391,0.000247665,0.001283372,0.0002169135],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995331,0.00007406998,0.0008337799,0.0005992551,0.001096687,0.001216203,0.00001958718,0.000005617345,0.0008238344],"genre_scores_gemma":[0.996008,0.00008332621,0.002029926,0.0009813447,0.0005660587,0.0000474555,0.0002101899,0.00002856739,0.00004516681],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0684689,"threshold_uncertainty_score":0.6969705,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03970374677695072,"score_gpt":0.3917280835614726,"score_spread":0.3520243367845219,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}